Skip to main content
FinSpry Logo
FinSpry
REGN logo
REGN
(NASDAQ)
Regeneron Pharmaceuticals, Inc.
$761.85-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Regeneron Pharmaceuticals (REGN) Stock Price & Financial Analysis

Regeneron Pharmaceuticals Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$745.00 - $770.11
52-Week High$821.11
52-Week Low$476.49
Open$767.04
Volume999.68K
Average Volume (3M)999.68K
Market Cap82.74B
Shares Outstanding108.60M
P/E Ratio (TTM)18.74
Forward P/E18.17
Price to Sales (P/S)5.89
Price to Book (P/B)2.70
EV/EBITDA14.31
Revenue (TTM)14.34B
Net Income (TTM)4.50B
Free Cash Flow (TTM)3.77B
EPS (TTM)$41.91
Profit Margin31.41%
Operating Margin25.66%
Return on Equity (ROE)14.41%
Debt to Equity0.06
50-Day MA$765.25
200-Day MA$661.52
52-Week Change25.97%
Annual Dividend$3.58
Dividend Yield0.46%
Payout Ratio8.54%
Last Dividend Ex-DateFeb 20, 2026

Frequently Asked Questions About Regeneron Pharmaceuticals

What is the current stock price for REGN?

As of the latest trading session, REGN stock trades at $761.85. The 52-week range is $476.49–$821.11, with a day range of $745.00–$770.11.

What is the P/E ratio for REGN?

Regeneron Pharmaceuticals's trailing P/E ratio is 18.7, meaning investors pay $18.7 for every $1 of annual earnings. The forward P/E is 18.2, reflecting analyst expectations for future earnings. Regeneron Pharmaceuticals operates in the Healthcare sector.

Does REGN pay dividends?

Yes, Regeneron Pharmaceuticals pays a 0.46% annual dividend yield ($3.58 per share). The payout ratio is 8.5%. The last ex-dividend date was 2026-02-20.

What do analysts recommend for REGN?

Based on 12 analysts, the consensus for REGN is Buy. The average 12-month price target is $NaN, representing a NaN% downside from the current price.

What is the market cap of REGN?

Regeneron Pharmaceuticals's market capitalization is $82.74B, classifying it as a large-cap company. Regeneron Pharmaceuticals operates in the Healthcare sector within the Biotechnology industry.